Hydralazine hydrochloride - CAS 304-20-1
Catalog number: B0084-065607
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C8H8N4.HCl
Molecular Weight:
196.64
COA:
Inquire
Targets:
Others
Description:
Hydralazine HCl is a hydrochloride salt of hydralazine (Apresoline) that is a direct-acting smooth muscle relaxant with an IC50 of 1.9 mM.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-065607 100 g $298 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
Hydralazine hydrochloride
MSDS:
Inquire
1.The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells.
Ruiz-Magaña MJ1, Martínez-Aguilar R1, Lucendo E1, Campillo-Davo D1, Schulze-Osthoff K2,3, Ruiz-Ruiz C1,4. Oncotarget. 2016 Mar 3. doi: 10.18632/oncotarget.7871. [Epub ahead of print]
Epigenetic therapies have emerged as promising anticancer approaches, since epigenetic modifications play a major role in tumor initiation and progression. Hydralazine, an approved vasodilator and antihypertensive drug, has been recently shown to act as a DNA methylation inhibitor. Even though hydralazine is already tested in clinical cancer trials, its mechanism of antitumor action remains undefined. Here, we show that hydralazine induced caspase-dependent apoptotic cell death in human p53-mutant leukemic T cells. Moreover, we demonstrate that hydralazine triggered the mitochondrial pathway of apoptosis by inducing Bak activation and loss of the mitochondrial membrane potential. Hydralazine treatment further resulted in the accumulation of reactive oxygen species, whereas a superoxide dismutase mimetic inhibited hydralazine-induced cell death. Interestingly, caspase-9-deficient Jurkat cells or Bcl-2- and Bcl-xL-overexpressing cells were strongly resistant to hydralazine treatment, thereby demonstrating the dependence of hydralazine-induced apoptosis on the mitochondrial death pathway.
2.Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low.
Sharma KJ1, Rodriguez M1, Kilpatrick SJ1, Greene N1, Aghajanian P1. Hypertens Pregnancy. 2016 Feb;35(1):123-8. doi: 10.3109/10641955.2015.1117098. Epub 2016 Feb 24.
OBJECTIVE: To determine whether the incidence of hypotension or adverse fetal heart tracing (FHT) category change differed following antepartum administration of intravenous (IV) labetalol versus hydralazine.
3.Heart Failure Update: Outpatient Management.
Wojnowich K1, Korabathina R2. FP Essent. 2016 Mar;442:18-25.
Outpatient management of heart failure (HF) is aimed at treating symptoms and preventing hospitalizations and readmissions. Management is initiated in a stepwise approach. Blockade of the renin-angiotensin system is a cornerstone of therapy and should be started, along with beta blockers, as soon as the diagnosis of HF is made. Other drugs, including diuretics, aldosterone antagonists, hydralazine, and nitrates, may be added based on symptoms and American College of Cardiology/American Heart Association stage. Despite a great interest in and theoretical benefit of naturoceutical products in the mitigation of oxidative stress and HF progression, none has been proven to be beneficial, and concerns exist regarding their interactions with standard HF drugs. Other nonpharmacologic interventions, including sodium restriction, regular exercise, and/or cardiac rehabilitation, should be initiated at diagnosis. HF often is progressive, and clinicians should be aware of late stage management options, including implantable devices, cardiac transplantation, and hospice care.
4.Novel epigenetic-based therapies useful in cardiovascular medicine.
Napoli C1, Grimaldi V1, De Pascale MR1, Sommese L1, Infante T1, Soricelli A1. World J Cardiol. 2016 Feb 26;8(2):211-9. doi: 10.4330/wjc.v8.i2.211.
Epigenetic modifications include DNA methylation, histone modifications, and microRNA. Gene alterations have been found to be associated with cardiovascular diseases, and epigenetic mechanisms are continuously being studied to find new useful strategies for the clinical management of afflicted patients. Numerous cardiovascular disorders are characterized by the abnormal methylation of CpG islands and so specific drugs that could inhibit DNA methyltransferase directly or by reducing its gene expression (e.g., hydralazine and procainamide) are currently under investigation. The anti-proliferative and anti-inflammatory properties of histone deacetylase inhibitors and their cardio-protective effects have been confirmed in preclinical studies. Furthermore, the regulation of the expression of microRNA targets through pharmacological tools is still under development. Indeed, large controlled trials are required to establish whether current possible candidate antisense microRNAs could offer better therapeutic benefits in clinical practice.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 7554-65-6 4-Methylpyrazole

4-Methylpyrazole
(CAS: 7554-65-6)

4-Methylpyrazole is a competitive inhibitor of alcohol dehydrogenase, which catalyzes metabolism of ethylene glycol and methanol to toxic metabolites. It is use...

CAS 186390-48-7 CP 346086

CP 346086
(CAS: 186390-48-7)

CP 346086 is a potent microsomal triglyceride transfer protein (MTP, MTTP) inhibitor. It reduces LDL cholesterol and triglycerides, and can be used for the trea...

CAS 126-27-2 Oxethazaine

Oxethazaine
(CAS: 126-27-2)

Oxethazaine, an effective topical anesthetic, could be used to relieve the pain caused by peptic ulcer disease and esophagitis.

CAS 170787-99-2 Efaproxiral Sodium

Efaproxiral Sodium
(CAS: 170787-99-2)

Efaproxiral, a synthetic allosteric modifier of hemoglobinoxygen binding affinity, has been shown to bind reversibly to hemoglobin, stabilizing the deoxyhemoglobi...

CAS 23651-95-8 Droxidopa

Droxidopa
(CAS: 23651-95-8)

Droxidopa(L-DOPS, SM5688) is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (a...

CAS 34670-43-4 4-Azido-L-phenylalanine hydrochloride

4-Azido-L-phenylalanine hydrochloride
(CAS: 34670-43-4)

4-Azido-L-phenylalanine is an unnatural derivative of L-phenylalanine, a nonpolar, essential amino acid that naturally occurs in the human body and is also used...

CAS 4044-65-9 Bitoscanate

Bitoscanate
(CAS: 4044-65-9)

Bitoscanate is an organic chemical compound used in the treatment of hookworms.

Gyki 13324
(CAS: 76123-41-6)

GYKI-13324 is bifunctional nitrosoureido derivative and alkylating agent. It can produce long-term or total regression of adenomatous, but only marginal growth ...

CAS 112809-51-5 Letrozole

Letrozole
(CAS: 112809-51-5)

Letrozole is a third generation inhibitor of aromatase with IC50 of 0.07-20 nM.

CAS 138736-73-9 HAMNO

HAMNO
(CAS: 138736-73-9)

HAMNO is a novel protein interaction inhibitor of replication protein A (RPA), which is involved in the ATR/Chk1 pathway. HAMNO acts by binding to the N-termina...

CAS 61281-38-7 Schisandrin A

Schisandrin A
(CAS: 61281-38-7)

Schizandrin A is extracted from the seeds of Schisandra chinensis (Turcz.) Baill that is reported to have liver-protective, antitumor, and antioxidant activitie...

CAS 36589-58-9 Eprodisate disodium

Eprodisate disodium
(CAS: 36589-58-9)

Eprodisate disodium is a sulfonated inhibitor of fibrillogenesis which coul be used in the treatment of amyloid A (AA) amyloidosis.

CAS 118525-35-2 Sagittatoside A

Sagittatoside A
(CAS: 118525-35-2)

Sagittatoside A is a natural compound isolated from traditional Chinese herb Yinyanghuo.

CAS 26647-82-5 Succinyl phosphonate

Succinyl phosphonate
(CAS: 26647-82-5)

Succinyl phosphonate was found to be effective inhibitors of alpha-ketoglutarate oxidative decarboxylation, catalyzed by both muscle and bacterial alpha-ketoglu...

CAS 155488-25-8 Sograzepide

Sograzepide
(CAS: 155488-25-8)

Sograzepide, a benzodiazepin derivative, has been found to be a gastric receptor as well as CCK2 receptor antagonist that could be useful against chronic atroph...

FR-78844
(CAS: 112856-39-0)

FR-78844 is used as a bone resorption antagonist.

CAS 3262-64-4 S-Propargyl-Cysteine

S-Propargyl-Cysteine
(CAS: 3262-64-4)

S-Propargyl-cysteine (SPRC) is a modulator of endogenous hydrogen disulfide (H2S) with antioxidant activity. SPRC is potentially used for the treatment of Alzhe...

CAS 2016795-77-8 EC330

EC330
(CAS: 2016795-77-8)

EC330 is a novel steroidal LIF inhibitor showed cytotoxicity in various cancer cell lines and NCI-60 cell line panel at low nano-molar range, blocked formation ...

CP-671906-01
(CAS: 332178-44-6)

CP-671906-01 is a neuropeptide Y1 receptor antagonists, increasing blood pressure and food intake in rat models.

CAS 343306-71-8 Sugammadex

Sugammadex
(CAS: 343306-71-8)

Sugammadex, a modified γ-cyclodextrin, with a lipophilic core and a hydrophilic periphery, is an agent for reversal of neuromuscular blockade by the agent rocu...

Chemical Structure

CAS 304-20-1 Hydralazine hydrochloride

Quick Inquiry

Verification code

Featured Items